<SEC-DOCUMENT>0001564590-21-024065.txt : 20210505
<SEC-HEADER>0001564590-21-024065.hdr.sgml : 20210505
<ACCEPTANCE-DATETIME>20210505161310
ACCESSION NUMBER:		0001564590-21-024065
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210505
DATE AS OF CHANGE:		20210505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38419
		FILM NUMBER:		21893390

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rcus-8k_20210505.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-03T17:28:42.8270191+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 3074d9f38802464e9bc8a9e81f6efe8d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:rcus="http://www.arcusbio.com/20210505" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
rcus-8k_20210505.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001724521_20210505_20210505">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0001724521_20210505_20210505">0001724521</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="rcus-20210505.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001724521_20210505_20210505">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-05</xbrli:startDate>
					<xbrli:endDate>2021-05-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549 </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:12pt;margin-top:0pt;margin-left:35.9%;margin-right:35.9%;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001724521_20210505_20210505">8-K</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:12pt;margin-top:0pt;margin-left:35.9%;margin-right:35.9%;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001724521_20210505_20210505" format="ixt:datemonthdayyearen">May 5, 2021</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:12pt;margin-top:0pt;margin-left:35.9%;margin-right:35.9%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0001724521_20210505_20210505">ARCUS BIOSCIENCES, INC.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in its Charter) </p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:35.9%;margin-right:35.9%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001724521_20210505_20210505" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityFileNumber" contextRef="C_0001724521_20210505_20210505">001-38419</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:33.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001724521_20210505_20210505">47-3898435</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0001724521_20210505_20210505">3928 Point Eden Way</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0001724521_20210505_20210505">Hayward</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0001724521_20210505_20210505">CA</ix:nonNumeric> <ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0001724521_20210505_20210505">94545</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0001724521_20210505_20210505">510</ix:nonNumeric>) <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0001724521_20210505_20210505">694-6200</ix:nonNumeric> </p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:35.9%;margin-right:35.9%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0001724521_20210505_20210505" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0001724521_20210505_20210505" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0001724521_20210505_20210505" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="letter-spacing:-0.1pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0001724521_20210505_20210505" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="letter-spacing:-0.1pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:34.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Titles of Each Class</p></td>
<td valign="top" style="width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:33.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top" style="width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:29.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Each Exchange on which Registered</p></td>
</tr>
<tr>
<td valign="top" style="width:34.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0001724521_20210505_20210505">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></p></td>
<td valign="top" style="width:1.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="top" style="width:33.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0001724521_20210505_20210505">RCUS</ix:nonNumeric></p></td>
<td valign="top" style="width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="top" style="width:29.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0001724521_20210505_20210505" format="ixt-sec:exchnameen">The New York Stock Exchange</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company:&#160;&#160;<ix:nonNumeric id="F_000006" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001724521_20210505_20210505" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.02<span style="margin-left:36pt;"></span>Results of Operations and Financial Condition. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 5, 2021, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months ended March 31, 2021. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration:underline;">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01<span style="font-weight:normal;margin-left:36pt;"></span>Financial Statements and Exhibits. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:45pt;"></td>
<td style="width:11.75pt;"></td>
<td style="width:411.25pt;"></td>
</tr>
<tr>
<td valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">
<p style="border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">99.1</span></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rcus-ex991_6.htm"><span style="text-decoration:underline;">Press release dated May 5, 2021.</span></a><span style="text-decoration:underline;"> </span></p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">104</span></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:56.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCUS BIOSCIENCES, INC.</p></td>
</tr>
<tr>
<td valign="top" style="width:56.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:37.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:56.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 5, 2021</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:0.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:37.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Terry Rosen, Ph. D.</p></td>
</tr>
<tr>
<td valign="top" style="width:56.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:37.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Terry Rosen, Ph.D.</p></td>
</tr>
<tr>
<td valign="top" style="width:56.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:37.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rcus-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rcus-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk507150033"></a>Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:-0.91%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gae5rxbs0yyr000001.jpg" title="" alt="" style="width:128px;height:45px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;"><a name="_Hlk507687381"></a><a name="_Hlk33444555"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.87%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Continued to advance our portfolio of anti-TIGIT antibodies: On track for the ARC-7 interim analysis for domvanalimab in 2Q21, </font><font style="font-style:italic;color:#000000;">and the first patient was dosed with AB308 </font><font style="font-style:italic;color:#000000;">in combination with zimberelimab </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Presented promising PFS and OS data for etrumadenant</font><font style="font-style:italic;color:#000000;"> in the &#8805;3L metastatic colorectal cancer setting at AACR</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><a name="_Hlk54242985"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Initiated the randomized portion of our ARC-8 study evaluating AB680, our first-in-class small molecule CD73 inhibitor, in pancreatic cancer following rapid completion of enrollment of the dose-expansion portion of the study </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Presented preclinical data on a novel series of HIF-2</font><font style="color:#000000;">&#945; </font><font style="font-style:italic;color:#000000;">inhibitors at AACR, including data on AB521, and remain on track to initiate clinical development for this program in 2H21</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Ended the quarter with $885 million of cash and investments</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk507687221"></a><a name="_Hlk507687221"></a>HAYWARD, Calif. &#8211; (BUSINESS WIRE) &#8211; May 5, 2021 -<font style="font-weight:normal;"> Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the first quarter ended March 31, 2021 and provided operational highlights.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54244980"></a>&#8220;Our ongoing clinical trials include six randomized studies with several that are expected to provide meaningful readouts over the next 12 months,<font style="color:#000000;">&#8221;</font> said Terry Rosen, Ph.D., CEO.&#160;&#8220;<font style="color:#000000;">W</font>e expect the next milestone in our anti-TIGIT program, the ARC-7 interim analysis, later this quarter.<font style="color:#000000;"> W</font>e also continue to generate substantial clinical<font style="color:#000000;"> evidence to support our first-in-class therapies targeting the ATP-adenosine axis having recently presented data from</font> ARC-3 which showed a doubling<font style="Background-color:#FFFFFF;"> of progression-free survival and overall survival for etrumadenant </font><font style="color:#000000;">and </font><font style="Background-color:#FFFFFF;">chemotherapy in late-line colorectal cancer compared to those reported for current standard-of-care therapies, and promising results for AB680 in first-line pancreatic cancer. </font>We will present initial data from ARC-6, evaluating etrumadenant plus zimberelimab and chemotherapy in metastatic castrate-resistant prostate cancer, at the upcoming ASCO Annual Meeting.<font style="Background-color:#FFFFFF;">&#8221;</font>&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Anti-TIGIT Program</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Domvanalimab (FcR-silent anti-TIGIT antibody)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;"><a name="_Hlk526493404"></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="text-decoration:underline;"><a name="_Hlk526493404"></a>Recent Highlights:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">First patient dosed in ARC-10, Arcus&#8217;s first global registrational trial</font><font style="color:#000000;">, evaluating domvanalimab + zimberelimab vs. zimberelimab vs. chemotherapy in first-line PD-L1&#8805;50%, locally advanced or metastatic non-small cell lung cancer (NSCLC). This study is designed to seek approval for both zimberelimab monotherapy as well as domvanalimab + zimberelimab in this setting.&nbsp;&nbsp;Gilead and Arcus have been actively collaborating to define a broad clinical development program for domvanalimab, and Arcus </font>expects to announce other registrational trials for domvanalimab later this year. </p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="text-decoration:underline;">Upcoming Milestones:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Results from the interim analysis for ARC-7</font><font style="color:#000000;">, a randomized, three-arm Phase 2 trial evaluating domvanalimab + zimberelimab </font><font style="font-style:italic;color:#000000;">vs.</font><font style="color:#000000;"> zimberelimab </font><font style="font-style:italic;color:#000000;">vs.</font><font style="color:#000000;"> domvanalimab + zimberelimab + etrumadenant in first-line PD-L1&#8805;50%, locally advanced or metastatic NSCLC are expected in the second quarter of 2021. A 50% or greater ORR for the zimberelimab + domvanalimab combination and clear separation from the zimberelimab arm would be considered a positive outcome for the interim analysis by Arcus and Gilead and could inform a potential opt-in decision. </font>We expect to present the data from this analysis at <font style="color:#000000;">a medical conference in the second half of 2021.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">AB308 (FcR-enabled anti-TIGIT antibody)</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">First patient dosed in the ARC-12 study evaluating AB308 in combination with zimberelimab</font><font style="color:#000000;"> in the second quarter of 2021. </font>By initially evaluating AB308 in combination with an anti-PD1 antibody,<font style="color:#000000;"> this study is designed to efficiently establish the safety and optimal dose of AB308 + zimberelimab </font>to facilitate advancement into a late-stage trial.<font style="color:#000000;"> We plan to evaluate AB308</font> in settings, such as certain hematological malignancies, where the depletion of TIGIT-bearing cancer cells could be beneficial.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">AB680 (CD73 inhibitor)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="text-decoration:underline;">Recent Highlights:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Completed enrollment of the dose-expansion portion </font><font style="font-weight:bold;font-style:italic;">and </font><font style="font-weight:bold;font-style:italic;color:#000000;">initiated the randomized portion of ARC-8</font><font style="color:#000000;">, a Phase 1/1b study evaluating AB680 + zimberelimab + gemcitabine/nab-paclitaxel (G/NP) in first-line metastatic pancreatic cancer.</font><font style="font-weight:bold;font-style:italic;color:#000000;"> </font><font style="color:#000000;">The randomized portion includes a control arm of AB680 + G/NP to help inform the design of a potential registrational trial. </font> Enrollment in ARC-8 has proceeded very quickly, and <font style="color:#000000;">if data continue to look promising, we anticipate discussing these data and the path to registration with health authorities in the second half of 2021.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><a name="_Hlk69803475"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Evaluation of the oral formulation of AB680 in healthy volunteers demonstrated the ability to achieve the desired circulating drug levels.</font><font style="color:#000000;"> Having an oral formulation of AB680 provides additional dosing flexibility and the ability to combine AB680 with other orally administered therapies.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Opened a second cohort evaluating the synergistic potential of AB680 and etrumadenant. </font><font style="color:#000000;">This cohort is part of our recently initiated ARC-9 </font>metastatic colorectal cancer (mCRC) plat<font style="color:#000000;">form study. The first cohort evaluating AB680 + etrumadenant, described last quarter, is part of our ong</font>oing ARC-6 metastatic castrate-resistant prostate cancer (mCRPC) platform study. <font style="font-weight:bold;font-style:italic;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="text-decoration:underline;">Upcoming Milestones:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Presentation of additional data from ARC-8</font><font style="color:#000000;">, including more mature data from the dose-escalation and initial data from the dose-expansion portions of the study, at a medical conference in the second half of 2021.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.25%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Etrumadenant (A<sub style="font-size:85%; vertical-align:bottom">2a</sub>/A<sub style="font-size:85%; vertical-align:bottom">2b</sub> adenosine receptor antagonist)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="text-decoration:underline;">Recent Highlights:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Presented very encouraging results </font><font style="font-weight:bold;font-style:italic;color:#000000;">for ARC-3, a Phase 1/1b trial evaluating etrumadenant in combination with mFOLFOX,</font><font style="font-weight:bold;font-style:italic;"> </font>at<font style="color:#000000;"> the 2021 AACR Annual Meeting</font><font style="font-weight:bold;font-style:italic;color:#000000;">. </font>The etrumadenant combination demonstrated a 4.2 month median progression-free survival and 13.6 month median overall survival, approximately double those reported for current standard of care therapies in the &#8805;3L mCRC setting.<font style="color:#000000;"> These are very encouraging data in heavily pre-treated patients. In addition, the etrumadenant + mFOLFOX combination was well tolerated, and etrumadenant did not appear to add significant toxicity to that expected for mFOLFOX-6. </font>ARC-9, our ongoing <font style="color:#000000;">randomized Phase 1b/2 platform study evaluating etrumadenant in combination with other agents in &#8805;2L mCRC, builds on the encouraging data from the ARC-3 study.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.25%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.25%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.25%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.25%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">Upcoming Milestones:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Presentation of initial data from the ARC-6 study in a poster at the 2021 ASCO Annual Meeting, June 4-8<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font>, titled: &#8220;<font style="color:#000000;">ARC-6: A Phase 1b/2, Open-Label, Randomized Platform Study to Evaluate Efficacy and Safety of Etrumadenant (AB928)-Based Treatment Combinations in Patients with mCRPC.&#8221;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Initial data from the Stage 2 randomized portion of this study are expected to be presented in early 2022.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Presentation of initial randomized data from ARC-4</font><font style="color:#000000;">, an ongoing study evaluating etrumadenant + zimberelimab + chemotherapy vs. zimberelimab + chemotherapy in EGFR</font><font style="font-style:italic;color:#000000;">mut </font><font style="color:#000000;">tyrosine kinase inhibitor (TKI)-relapsed and refractory NSCLC, expected at a medical conference in the second half of 2021.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">HIF-2&#945; inhibitor</font><font style="text-decoration:underline;font-weight:normal;"> </font><font style="text-decoration:underline;color:#000000;">Program </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Initiation of clinical development for our HIF-2</font><font style="font-weight:bold;color:#000000;">&#945;</font><font style="font-weight:bold;font-style:italic;color:#000000;"> inhibitor</font><font style="color:#000000;"> is anticipated to occur in the second half of 2021. At the 2021 AACR Annual Meeting, we presented details of our Hypoxia-Inducible Factor 2&#945; (HIF-2&#945;) research program, including the design of a novel series of HIF-2&#945; inhibitors, which has resulted in the identification of molecules such as AB521, with excellent potency, selectivity, biological activity and pharmacokinetic properties suitable for further development.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Financial Results for the First Quarter 2021 Ended March 31, 2021</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Cash, cash equivalents and investments </font><font style="color:#000000;">were $884.9 million</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">as of March 31, 2021, compared to $735.1 million as of December 31, 2020. The increase was primarily due to gross proceeds of $220.4 million received upon the closing of the private placement of common stock under the Amended and Restated Stock Purchase Agreement with Gilead in February 2021, partially offset by cash utilized for our operations. We expect cash, cash equivalents and marketable securities on-hand to be sufficient to fund operations at least through 2023.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Revenues:&nbsp;&nbsp;</font><font style="color:#000000;">Collaboration and license revenues were $9.5 million for the three months ended March 31, 2021, compared to $1.8 million for the same period in 2020. In the three months ended March 31, 2021, we recognized $7.7 million in collaboration revenues related to Gilead&#8217;s ongoing rights to access our research and development pipeline in accordance with the Gilead Collaboration Agreement, as well as $1.8 million under the Taiho Agreement. In the three months ended March 31, 2020, we recognized $1.8 million under the Taiho Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">R&amp;D Expenses:</font><font style="color:#000000;"> Research and development expenses were $66.4 million for the three months ended March 31, 2021, compared to $23.1 million for the same period in 2020. The increase was primarily due to $15.0 million of sublicense and milestone expense in the 2021 period as compared to no amounts in the 2020 period. Increases in employee compensation costs, approximately $4.4 million of which consists of non-cash stock-based compensation, also contributed to the overall expense increase and were driven by increasing headcount and 2021 stock awards. Manufacturing and clinical costs increased as well due to the increased number of clinical programs and studies compared to the same quarter in the prior year. Office and facilities expense increased as we continued to grow. The overall increase in research and development expenses is partially offset by a $4.9 million reimbursement by Gilead of certain applicable costs of developing zimberelimab, including $4.0 million reimbursement related to milestone expense incurred.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">G&amp;A Expenses:</font><font style="color:#000000;"> General and administrative expenses were $15.8 million for the three months ended March 31, 2021, compared to $7.0 million for the same period in 2020. The increase in expense was due to increases in employee compensation, approximately $4.9 million of which consists of non-cash stock-based compensation, driven by increasing headcount and 2021 stock awards. Additional increases in finance and legal expenses were largely driven by costs incurred to support our growth </font></p></td></tr></table></div>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="color:#000000;">and ongoing compliance with public company requirements, and we incurred additional facilities expense due to our expanding headcount and office space.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.62%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">Net Loss:</font><font style="color:#000000;"> Net loss was $72.6 million for the three months ended March 31, 2021, compared to a net loss of $27.8 million for the same period in the prior year. The increase in net loss as compared to the same period in the prior year was primarily attributable to our expanding operations including advancements in our clinical pipeline and related milestone payments, partially offset by increased revenues due to the Gilead Collaboration Agreement.</font></p></td></tr></table></div>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Arcus Clinical Study Overview</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:103.05%;">
<tr>
<td style="width:11.73%;"></td>
<td style="width:29.89%;"></td>
<td style="width:30.86%;"></td>
<td style="width:15.4%;"></td>
<td style="width:15.18%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Trial Name</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Arms</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Setting</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">NCT No.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARC-3</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Etruma + mFOLFOX</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CRC</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial Study</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCT03720678</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARC-4</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Etruma + Zim + Carbo/Pem vs. Zim + Carbo/Pem</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TKI R/R EGFRmut NSCLC</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ongoing Randomized Phase 1/2</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCT03846310</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARC-6</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Etruma + Zim + SOC vs. SOC</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2L/3L CRPC</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ongoing Randomized Phase 2</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCT04381832</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARC-7</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zim vs. Zim + Dom vs. Zim + Dom + Etruma</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1L NSCLC (PD-L1 &#8805; 50%)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ongoing Randomized Phase 2</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCT04262856</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARC-8</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AB680 + Zim + Gem/NP vs. AB680 + Gem/NP</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1L PDAC</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ongoing Randomized Phase 1/1b</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCT04104672</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARC-9</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Etruma + Zim + mFOLFOX vs. SOC</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2L/3L/3L+ CRC</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initiated Randomized Phase 2</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCT04660812</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARC-10</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Chemo vs. Zim mono vs. Zim + Dom</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1L NSCLC (PD-L1 &#8805; 50%)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initiated Registrational</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCT04736173</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARC-12</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AB308 + Zim</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advanced Malignancies</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initiated Phase 1/1b</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">NCT04772989</font></p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PACIFIC-8</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Durva &#177; Dom</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Curative-Intent Stage 3 NSCLC</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected initiation 2H21 Registrational</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NA</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CRC: colorectal cancer, NSCLC: non-small cell lung cancer, CRPC: castrate-resistant prostate cancer, PDAC: <font style="Background-color:#FFFFFF;">pancreatic&#160;ductal adenocarcinoma, Durva: durvalumab</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Arcus Biosciences</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arcus Biosciences&#160;is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has five molecules in clinical development:&#160;<font style="font-weight:bold;">Etrumadenant (AB928)</font>, the first dual A<sub style="font-size:85%; vertical-align:bottom">2a</sub>/A<sub style="font-size:85%; vertical-align:bottom">2b&#160;</sub>adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, and pancreatic cancers.&#160;<font style="font-weight:bold;">AB680</font>, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:8pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel.&#160;</font><font style="font-weight:bold;">Domvanalimab</font><font style="font-weight:bold;"> (AB154)</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for f</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">irst</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-line treatment of </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PD-L1 &#8805; 50%</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> locally advanced or </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">domvanalimab</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+ </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">zimberelimab and </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">domvanalimab +</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">etrumadenant</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+ </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">zimberelimab. In addition, domvanalimab has advanced into </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARC-10, Arcus&#8217;s &#8220;two in one trial&#8221; to support the potential approvals of both zimberelimab and zimberelimab + domvanalimab and is expected to advance into a registrational study, in collaboration with AstraZeneca, evaluating the </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">curative-intent stage </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> NSCLC setting later this year.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-weight:bold;">AB308</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, an anti-TIGIT antibody that is </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FcR</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enabled, </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advanced</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> into clinical development to investigate additional indications, with a focus on hematological malignancies</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-weight:bold;">Zimberelimab (AB122)</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Arcus&#8217;s anti-PD-1 monoclonal antibody, was in-licensed</font><font style="font-weight:bold;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to enable the development</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of Arcus&#8217;s combination regimens and</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is being evaluated</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> various combinations across the portfolio. For more information about Arcus Biosciences, please visit&#160;</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">www.arcusbio.com</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein, including, but not limited to,&#160;Arcus&#8217;s expectations for meaningful readouts and ability to generate substantial clinical evidence as set forth in Dr. Rosen&#8217;s quote, the potential for the ARC-7 interim analysis to inform a potential opt-in decision by Gilead, Arcus&#8217;s anticipated milestones and associated timelines described herein and Arcus&#8217;s expectation that its cash, cash equivalents and marketable securities on-hand will be sufficient to fund operations through at least 2023 are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.&#160; All forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Arcus&#8217;s actual results, performance or achievements to differ significantly from those expressed or implied.&#160;&#160;Factors that could cause or contribute to such differences include, but are not limited to: the inherent uncertainty associated with the COVID-19 pandemic, including the <font style="Background-color:#FFFFFF;">duration and/or severity of the outbreak and actions by government authorities to contain or slow the spread of the virus; </font>the inherent uncertainty associated with pharmaceutical product development and clinical trials; <font style="Background-color:#FFFFFF;">our dependence on our collaboration with Gilead for the successful development and commercialization of our investigational products; </font>delays in our clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials; the unexpected emergence of adverse events or other undesirable side effects; risks associated with preliminary and interim data; and changes in the competitive landscape for our programs.&#160; Risks and uncertainties facing Arcus are described more fully in Arcus&#8217;s quarterly report on Form 10-Q for the quarter ended March 31, 2021 filed on May 5, 2021 with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Arcus name and logo are trademarks of Arcus. All other trademarks belong to their respective owners.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Arcus Biosciences</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Arcus Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Katherine Bock</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VP Investor Relations &amp; Corporate Strategy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(510) 694-6231</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">kbock@arcusbio.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARCUS BIOSCIENCES, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Operations and Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"> (In thousands, except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,461</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total collaboration and license revenues</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,461</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,387</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,142</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,821</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,008</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,208</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,150</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,747</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-operating income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on deemed sale from equity method investee</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">482</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share of loss from equity method investee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(482</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-operating income, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">647</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,593</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,753</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,639</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,529</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.08</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.63</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of shares used to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; compute basic and diluted net loss per share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,082,161</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,282,607</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Selected Consolidated Balance Sheet Data</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(unaudited)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"> (In thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and investments in marketable securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">884,912</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">735,086</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">935,119</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">772,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270,329</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269,988</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">664,790</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">502,304</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Derived from the audited financial statements for the year ended December 31, 2020, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 25, 2021.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gae5rxbs0yyr000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gae5rxbs0yyr000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" !G 2@# 2(  A$! Q$!_\0
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MZ/\ B*J_X)X?]$C^,G_A.Z5_\LZT_P!7\Z_Y\2%[:CW/TPHK\^_AI_P<R?\
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MK-/' B'!:2Y,* ,#NX;;Z%3A_.J-/GE0E;RL_P $VR%6HO2Y]\45\K_ME_\
M!8O]BS]AOQ;X \*?%CQ-J6J+\0[%=1TW4O",=M?VUAICR1I%J-QB=7^S2;Y&
MC>%)3(+>;:"5 ;ZHSQFO-J8;$4:<:DXM*5[-];:.WH6I1;L@HK\SA_P=5_\
M!.\_\TD^,?\ X3NE?_+.E_XBJO\ @GA_T23XR?\ A.Z5_P#+.O2_U?SK_GQ(
MCVU'N?IA17P]^QK_ ,%^/V-OVXOVB="_9E^$OP\^)-AKWB".[>RNO$&C6$-H
M@M[66Y?>T-]*XRD3 80Y8@' R1]PUP8K!XK U/9UX.+M>S[?TBXRC-7BPHKS
M/]L3]JOX=_L2?LY>(OVGOBOI&LWWA_PS]C_M"U\/V\4UX_VB\AM$\M)98D.)
M)T)RZX4,1DX!^&_^(JK_ ()X?]$D^,G_ (3NE?\ RSK?"Y7F&.INI0IN23M=
M=_Z8I5*<':3/TPHK\SS_ ,'57_!.\=?A)\9/_"=TK_Y9U^A7P5^*WAWX[_!O
MPE\</"%G>6^D^,O#-AKNEV^I1HEQ%;W=NEQ&LJHSJL@20!@K, <X)'-3BLMQ
MV!BI8BFXI[7"-2$_A9TU%>+_ +6O_!0S]CC]AW3X;C]I?XYZ3H%Y=1K)8Z%&
M'N]2N4;S-LB6ENKS>46B=/.91$&&UG!(%?"/CC_@[#_9+T]8S\-OV9OB+JQ/
M^M_MR:PT[;]/*FN=WZ5IA<GS/'1YJ%)M=]E][LA2JTX;L_5:BOS/^$?_  =,
M?L#>-M6T_1/B=\//B%X+:[D*W>K7&E6]_I]D-I.YVMYC<,"1M^2W8Y(XQDCZ
MN^)O_!4#]C?X>_L=ZI^W+H?Q1MO&7@72I+6"9O!MQ!<WCW5P\"I:>3+)&8[D
M"XC=X)3')&F691BBME&9X>I&%2E).3LM-&WLK[7"-6G)73/H*BO,?V./VL/A
MO^V_^SIX?_:<^$FF:Q9:#XC:[6SL]?MXHKR(V]W-:N)$AEE1<O"S##G*LI."
M2 5P5*=2C4=.:LTVFNS6YHG=71Z=1114 %%%9_B[Q9X;\!^%-4\<^,M;M]-T
M?1=/FOM6U*\D"16EM"ADEE=CT545F)[ &A)MV0'XC?\ !U7^UO\ \)9\7_!'
M[&'A?6=]CX3L3XB\506]XKH=2N5,=I%+'C,<L-L))!D_,FH@XZ$_HG_P11_9
M'M/V4O\ @FUX&\#:_H$<.M^+[%O$_BZ&:&96DNK]%=(IHIO]7)%:"UMI$"JN
MZW8X)+$_B!\ -#U__@L+_P %BK'4OB!ILMQIOQ ^($NM>(M/O[R9A;>'[7,[
M6!G@"NNVR@6SCD&SYC%RI.1_3J.!BOLN(?\ A-RO#9;'=+FEZ_KK?[D<M#]Y
M4E4^2/Y)_P!O?]F*Y_8V_;(^(G[-4B7'V7POXDECT62]NHYYY=+E"W%C+*\2
MJAD>TE@=\*N&9AM4C _:'_@UQ_:B'Q3_ &+=>_9GU4_\3#X5^(6:Q$=J$0Z7
MJ3S7,67W$R2"Z74-WR@*AA'/-> ?\'7/[+4FC^//AU^V7X?TV3[-K%E)X4\2
MS)'&L4=U"7N;)SC#O++$]VI8Y 2SC'' /R7_ ,$$/VI1^R__ ,%+/!9U.3;H
M_P 0=W@S6-MMYCC[=)']D*_, F+Z.TW/SMB\S@YKZ+%?\+_"RJ+6:7-_V]'1
M_>KV]3GC^YQ-OZU/Z:J***_*STCSGXS_ +('[*W[1FLVWB/X]_LZ^"_&6H6=
MG]DL[[Q)X<M[R:"#<6\M'E0LJ[F9L @9)-?S9?\ !9O]FOX6_LF_\%&?'WP8
M^"?AQ='\*VJZ;=Z3I2W$DPM1<:?;S2H&D9FV^<\I ).U2 . *_J3K^:W_@XQ
M./\ @K)X^_[!.A_^FNVK[;@FO6>92IN3Y>1Z7=MX]/FSDQ<8^SO;J?<7_!'#
M_@CC_P $Z?VKO^"=7@'X\_'KX 2:YXJUR35AJ>J+XLU6U\X0ZK=P1_N[>Z2-
M<11(ORJ,XR<DDGZ=_P"(>C_@D3_T:K+_ .%YKG_R;2?\&\W_ "B*^%?_ %VU
M[_T^7]?:E>3FF:9G3S.O"%>:2G))*4DDKO1:FM.G3=--I;(_.OXV?\&QO_!-
M_P"(ND7"?"V'QA\/=1^RR+8SZ/XA>^MUG*$1O-%?><\B*V&*)+$S 8#KG(_%
M/]M[]C_XW?\ !,7]KB?X0Z_XME35M#FMM:\&^,M">6S:[MBY>UOX"")()4DC
M93M8^7-!(%=PJR-_6!7XE_\ !VU<>"C\0O@A;6#V?_"1KHNNMJJIM^T"R,MD
M+7?WV>8+S9GC/F8[U['"^=9A6S&.%K3<XR3WUM9-WN]>EOF8XBC3C3YDK'V5
M_P $'/\ @IMXI_X*%_LYZKX<^,/[SXA_#F>VM/$6J1QA8]8M;@2&UO=JJJQR
MMY,T<B+D;H1(-HF$:?:WC;QIX6^''@S5OB'XYUR#3-%T'39]0UC4KIL1VMK#
M&TDLKG^ZJ*S'V%?A3_P:A>'_ !==?MG?$7Q79V5PV@V7PQ:TU*Y5#Y,=W-J-
MH]LC'H':."Z*@\D(^.AKUG_@ZA_;>U?2K3PG^P)X)U&>WAU.UC\3^.I(F*K<
MPB5X["S)27YE\V*:XDBDCQNCLW1LAA7+C\CIUN)G@Z&D79O^ZK7?_ 7FD53K
M6P_-(^2_^"L7_!<;XX_M[ZSJ?PA^%5_>>#_A#%?,MOH]LYCO-?C7*K+J$BG)
M1LEQ:J?*4E=_FO&D@^D?^"8G_!L__P )]X4T7X\?\%"=0U;2;?4(UN['X5:?
MFUO/)W1M'_:5Q]^ N@D#6L029 \9::*19(5\B_X-I_V%]'_:2_:TU#]I+XAZ
M='<^'?A%';7FFVLO2ZUV=G^R,5:-E=(%BFG.'1TF%H?F4L*_H1KT,^S6.3)9
M=ERY+)<S6^JVOWMJWOM:Q%&G[7]Y/4^=? ?_  2._P""9GPY\,1^$O#_ .Q#
M\.[BUC#!9M>\/QZK=')SS<WOFS-[9<X' P*^<_VQ/^#:O]A/XZ>&+S4/V==-
MNOA1XN9I)K6\TNZFO-+N)6D1BD]G/(VR,*KJ@MGA"&3<5D"B,_HM17R5'-LS
MP]7VD*TK^;;OZIW3^9TRITY*S1_(Y^V'^R]^T/\ L:?&BY_9S_:1TBXM=6\/
M6^S26%P\UE=:?)+))'<6,A #6TDCS.,!2LC2K(J2K(B_TV_\$ROVAG_:J_8#
M^%/QQO=5O=0U#5/"-O;Z]?:A&J2W.J6A-G?2D*2,-=6\[*>,J0<#.!\\_P#!
MP[^P7IO[6'[%.H?&GPMI*'QO\([>XUO3KA6VM=:2%#:C:G+JN!$@N%)5WWVH
MC3'G/GR;_@U)^/5SXR_9:^(G[/6I3ZA/+X'\70:G8RW5T7AAL]2@8+;0J3^[
M"SV-U*P&%+7)/4L3]3FV+CGG#L<59*=*5I+UTNO)NS^]:VN<]./L:_+T>QZY
M_P %2_\ @DG^P'K/["7Q.\:^"?V:_"G@SQ#X,\%:EXCT/7?!^BQ:?/'/8VTE
MSY3B$*LT<BQ&)ED# +(64!U1E_ ?]D#X8>&/C9^UK\+?@SXV2X.B^+OB-HFB
MZP+67RY3:W5_#!+L;!VMLD;#8.#S7]1?_!1W_E'G\>?^R,^*/_33<U_,K_P3
MC.?^"AGP%_[+1X7_ /3M;5Z'"F*Q%3*\0YS;Y;VN[V]WH1B8Q52-D?TV? S_
M ()Y?L/?LTZMI/B/X&_LM>"_#NL:';M!IFO6NBQOJ42-$8GS>2;IW9HV969G
M+,&.2<FO9***_.:E:K6ES5).3[MMO\3N24=C!^)?PO\ AQ\9O!-[\-?BWX$T
MGQ-X>U+R_P"T-$US3X[JUN?+D65-\4@*MMD1'&1PR@CD"OQD_P"#DS_@FG^R
M[^S;\(?!?[47[.7PPTCP5<7WC#_A'_$6DZ';O%;7WG6<L]O,L(;R8#$+*92(
MT7S#<98DJ*_;FOS+_P"#J\X_X)Y>#?\ LLVG?^FG5Z]OAO$8BEF]&$)-)O57
MT=UU6W](RQ$8NDVT<3_P;\?\$KOV.?B1^Q)I?[4OQ[^"GA_QUXD\7:QJ:V;>
M)+)KJ#3[&"X^RK;BWD=H&?S;:67SO+$@$^S.%Y^HO^"O'[=>A?\ !+/]ARW7
MX*Z3INF>*-46'PS\,='M;.#[-I:QPX:X^SEE'D6MNF%"HZ"5[9&38[$9_P#P
M;P?\HCOAC_U]:[_Z>KVOD7_@[DT769]'^ ?B.#2KAM/M;KQ-;75\L+&&&:5=
M+:*-GZ*SK#,RJ3EA$Y&=IQZ,5+,^+'0Q,G*"G+1O2T;M*W9V2,_X>&O'LCXQ
M_P""8'_!.CXP?\%D?VDO$GC3XQ?%O65T#1)K6\^(?C*^NOM>J7SS,1%:0-.2
M3-)'#*!*P=(5C!96^2-_VP^$7_!#S_@EO\&])73M'_9*T'6IFMHXKK4/%\DV
MK2W#(H!E(NG>.)V/S-Y21KD\*!@#\[/^#8C_ (*&_"KX/WWB3]AKXP^(K'0Y
M/&/B2+6/ 6I72>7'>ZG)#';3V$LS2;5DD6"U-NFP!W$R;R[PQM^X><]*KBG,
M,THYBZ"DX4TERI-I-66NEKZ_=:P8>G3=.^[/@']IS_@V\_X)Q_''P]>GX6>#
M]2^%_B.;SI;76/#&I37%MY[1D();*YD>(P*V&,<!MV;&!(N<U^(O[??[ G[3
MO_!-[XD-\$OC="SZ+KCKJ&@:YI,TC:3KZP!D$J9 _?PB=T>)P)(O/R,QS(\G
M]7%>1_MR?L;_  M_;P_9L\0?LZ_%6Q@\G4H#+HNL/9B:;1-216%O?PC<IWQE
MB" R^9&\D3'9(P//D_%&,P591Q,G.F][ZM>:>^G;[K#JX>,HWBK,_/G_ (-/
M/C8GB#]G#XH?L]3V<WG>%?&%KKD-Y+=[EDAU&V\GR4CQE!&^G.Y.2";D< @E
MBO!?^#?[X,_M1?L?_P#!57QA\(O'?P/\67&EQZ=JW@[Q9XCT_2;O^Q=,O8#'
M?6]S+.T0CV3):[8&?872^C9>'P2N;BBG3AG$YTVFII25O-?JU?YE8=OV23Z'
M[N4445\\;A7Y_?\ !R!^UO\ \,Z_\$^[SX5>'=;^S>(_BQJ"Z!:I;WGESIIB
M@2ZA*%P?,C:,):NO'%^.>Q_0&OYQO^#CS]K?_AHW_@H-??##PYK7VCPW\*=/
M7P_:I#>&2!]28B74)0NT>7*)2EI(.<FP4Y[#Z'A? _7LVA=>[#WG\MOQM\KF
M&(GR4GYGU'_P:??LOQQV7Q,_;-UFV7S))(_!OAV1;A@RJ/*O;_='C:0Q.G;'
MR2"DHXYS^RU>)?\ !.+]EW_AC+]B#X<?LYW4+)J6@^'DD\0*UTLP&J7+-=7H
M6154-&+F:94.,B-4!)QD]#^T_P#MB_LR?L9>"%^(/[37QCTGPGI\S%;*.\D:
M2ZOF#QJRVUK$KSW)4RH6\I&V*VYMJ@L.;-L34S;-JDZ:<KNT4M;I:*R\[7^9
M5.*I4TF><_\ !7#]DY_VS?\ @G[\0_@_H^D?;/$-OI)UKPBD>GK<7!U2R/VB
M*& ,R[)+@(]IO!!5;I^HRI_E=1VC99(V964Y5ESD'UK]COVDO^#G+XY?&7Q%
M<?"K_@FY^S)?+-/#(+?7O$FFMJ6JR1^2NZ6'3K4M% T4A8AY)+A&4*6C7)4?
ME?\ M+?!3X[_  0^)\^E?M#_  \7PWKVN1MK,=I;VMI#:SP332CSK9+/_1UA
M\Q)4580(T,90*NW:/MN%7++9O+\54A&I-<\:;E'VG*K*4N2]^5>[=]&[.S9S
MXBG4J4_;PB^5.SE9\M]TK[7WT/Z1/V/_ /@KA^QW\8OV3_ /Q;^,W[57PW\*
M^*=8\+PR^)M#U[Q98:;<PZA%N@NRMK-/YBQ-<0S&+():,H1UJOKO_!>#_@DU
MX=U"33;_ /;#TN22)RK-8^'=5NHR?:2&U9&'N"17XQ_\$,_V"?V:/^"@WQQ\
M7?"[X[Z]JL6IZ)X?AUC0=*M4=;6]MEG\F[,TD<D<BNCS6FQ589#R$_=%?J];
M_P#!M;_P2M4+-=_"[Q(TQ7$C0^-M16,GU"&9MOYFOC\VIY/E6;5,+5H8B25F
MI0]@H:ZV7/54M-FW%*ZT;.VA2E6P\:GM8)OH^>ZMU=H-:^3?F?5W[+?[7O[.
MO[:?P^N_BI^S+\1X_%&@V.L2:5=ZA'IMU:^7=I%%*T6RYBC?(CGB;(7'S]<@
M@?S[_P#!QC_RED\?9_Z!.A_^FNVK]]OV,?V(/V??V!OAAJ'P?_9NT#4--T/5
M/$$NM7<&HZM->.UW)!! S!Y6)5=EO$-HX!!/4FOP)_X.,O\ E+)X^X_YA.A_
M^FNVKUN#949YU.5&,E'D=E/EYEK'?E;C?T;1RXR+C3LVGKNKV^5TG]Z/N;_@
MC9_P6&_X)S?LJ?\ !.?P!\!_CY^T3_8/BO1)-6.J:5_PB.KW7DB;5;N>+][;
MVDD;;HI4;Y6.-V#@@@?3Y_X.#O\ @D(/^;N/_+!U_P#^0*^1/^"0G_!$[]@+
M]K[_ ()[^ _VA/C?\/\ 6K[Q/KTFJKJ5U9^)KFWC?R-4NK>/$:,%7$<2#CJ1
MGJ:^(?\ @L[_ ,$J/$W_  3C^.G]M^!])O+KX3>+;EG\&ZQ),9VL9MNZ33;E
ML965/F:,MGS8<$,[QS!.O^S>'<SSBK1<ZBJ.4F]8I-W=U'1OTOK8S]IB*=).
MRMH?J]\>/^#E[_@FK\,?"KZE\)O$GB3XDZM)#,+/2]#\-W5A&LPC)C^T3:A'
M!Y<3/A2\:3.H)/EMC!_%?]J#]H/]IS_@KM^VJ_C:S^'][J_BGQ(T>F^$O!?A
MU9;H:?8PJS);Q;B3M4>;/+(=J;GFE(C4D+]*?\$(?A%_P2]_:_\ %]Y^RO\
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M$,K,,@M+) H('8DK^=O[1_[)?[27[(GC+_A _P!I/X,ZYX1U&1I%M/[3M?\
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M[IQTTO4UC'[*DW&;^K64T<KPL,5F<>:I-7A1VLNDZEM;=H:-]6M4>0_L??\
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MQ:\:WAM]'\+_ !)T+5]6G52QCM;;4()I6P,DX1&. "37]=QY&*_F*_X+'_\
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MR:;\/]/GOI;VUR/,47-VEN+60C(5O(G4=2#]VOV\HKTZG%V=U(\JFEYJ*O\
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M?0ZK^V%^U!906T=U(L^@_#6S>:2XA\O]VZW][&@A<2'+(;20%5P&!;*_K/\
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MXH_8._;+\*^')O%VD^$T\6^$_&G@E7CT_7=!-REF6GMY9'DMKH7!(*CY&Q(
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M_P"%5C2#XH_LFY_X1L>(#*+ W_E-]G^T^3^\\CS-F_9\^W=MYQ114@? L_\
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*;'E++<%%%(#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rcus-20210505.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-03T17:07:08.1782408+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 3074d9f38802464e9bc8a9e81f6efe8d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:rcus="http://www.arcusbio.com/20210505" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arcusbio.com/20210505" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.arcusbio.com/20210505/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20210505_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20210505_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>rcus-20210505_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-03T17:07:08.1792414+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 3074d9f38802464e9bc8a9e81f6efe8d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>rcus-20210505_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-03T17:07:08.1792414+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 3074d9f38802464e9bc8a9e81f6efe8d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arcusbio.com/20210505/role/TemplateLink" xlink:href="rcus-20210505.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rcus-20210505.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>rcus-8k_20210505_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rcus-20210505.xsd" xlink:type="simple"/>
    <context id="C_0001724521_20210505_20210505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0001724521_20210505_20210505" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0001724521_20210505_20210505" id="F_000004">0001724521</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0001724521_20210505_20210505" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0001724521_20210505_20210505" id="F_000002">2021-05-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0001724521_20210505_20210505" id="F_000003">ARCUS BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001724521_20210505_20210505" id="F_000005">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0001724521_20210505_20210505" id="F_000007">001-38419</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001724521_20210505_20210505" id="F_000008">47-3898435</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001724521_20210505_20210505" id="F_000009">3928 Point Eden Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001724521_20210505_20210505" id="F_000010">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001724521_20210505_20210505" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001724521_20210505_20210505" id="F_000012">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001724521_20210505_20210505" id="F_000013">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001724521_20210505_20210505" id="F_000014">694-6200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0001724521_20210505_20210505" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0001724521_20210505_20210505" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0001724521_20210505_20210505" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0001724521_20210505_20210505" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0001724521_20210505_20210505" id="F_000019">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001724521_20210505_20210505" id="F_000020">RCUS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001724521_20210505_20210505" id="F_000021">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001724521_20210505_20210505" id="F_000006">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140150978965000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  05,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCUS BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001724521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3898435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3928 Point Eden Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">694-6200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCUS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ HH&E4I>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( **!I5+&*-C-/@0  $@0   8
M          " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " "B@:52GZ ;\+$"  #B#   #0              @ & #   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( **!I5*7BKL<P    !,"   +
M  "  5P/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( **!I5(<.&7J/P$  #P"
M   /              "  440  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "B@:52)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "B@:5299!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rcus-8k_20210505.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="rcus-8k_20210505.htm">rcus-8k_20210505.htm</File>
    <File>rcus-20210505.xsd</File>
    <File>rcus-20210505_lab.xml</File>
    <File>rcus-20210505_pre.xml</File>
    <File>rcus-ex991_6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rcus-8k_20210505.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "rcus-8k_20210505.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rcus-20210505_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rcus-20210505_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "rcus-20210505.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rcus",
   "nsuri": "http://www.arcusbio.com/20210505",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "rcus-8k_20210505.htm",
      "contextRef": "C_0001724521_20210505_20210505",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "rcus-8k_20210505.htm",
      "contextRef": "C_0001724521_20210505_20210505",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.arcusbio.com/20210505/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001564590-21-024065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-024065-xbrl.zip
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M?A*N,I8MUR5&6R?V_QN6?&(*V?I.53]?&E2>*?>98O]V$ONQ^HP=!5HO(4M
MJ0XT]+4KV<Z%U[W6NY?L9;C;:ZN=9D\NM\H;X_H_4$L#!!0    ( **!I5)^
M0 Z4%0<  (I)   5    <F-U<RTR,#(Q,#4P-5]L86(N>&ULS5QM;]LV&/P^
M8/^!<[^T6&5)3IK&09,B<Y+!F)L$<;H5&X9"EFB'&$T:I)S8_WZD7AS+IF1)
MIFH&!>(HY-W#NWLD2K7SZ?-BBL$S9!Q1<MYRVTX+0.+3 )')>6O.+8_["+4
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M:,='I:BZ>_)UL)26_T!Y;]PC5J!+^V)>&]T<,?_,JY3O_P502P,$%     @
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M7Y_>L_) ,/JU3(<@K"WJ/-*)C&\77/.M8)L[N_VV(;>11MD-V#B:@JGI9B;
MG<G@.XX"X%'0N<=DZ 0J8'4#4A<'MD%V4I< MST0<RS0BG39TI%GRW,\T4I<
MLRTJMAN7I*X0.2*7>%4B^8E[TN+JWL'XPF..^RPVH:!&,"U7@!*CH+BHZX*F
ML50.'V!OIH)$C$]47:A.@I%@C*C;2T #*CWWA0I8PE>-:&B-H/,T#!V'(/B)
M&LH.!Z9Q& J7RQ'"@E9UQ <\($WP@0DX @Q4&M),Y1,FY^&@*A:!K0?M/+U0
M4?LP)$2\<7=ZF2HZ-<J)0#D@* )3MV*:=GDPRR).H_!P/A%SP-+X!L3*$=AY
M9;F@R&9@$&V"R<HF8( [S%:_C5-%=K SOB>C('!L9XC16-(W.D+RTG$$R0$V
MB(?)R+/"DLVL^-AC2VTWX26S@)9TK[&0Q] ='DV/B#Z"Y20R'/P+X,,)XT .
MIP/N1* I8&E 9 3_$6(]1@)/XR##;6DV0VJ@K8[S5@MSW6(_,S-M;W'G[ C<
M!(OYZ@83]J2$ Q-D68 8![< AI;1Q296%@89@JQ%0#S'^>J>N+?LFVU*M3<U
MW5C<N<Y*5;&V3UWLCN= <$\S4O:Q-,@/I.'Q?K+IM+9Z!\RFM^UJQ\C-<QMW
MF=A)K1YSQ33.D@T"&='1@.(:-:AB9JLL>2!_]<#^.L+X15RZUL,]B<FY]K3E
MCJ2^;I_G'?#U)O2\^Q)DE5.\KT/9\L=C]%P=^(TRY!63EN!^$)^'7Y#D!#VC
M"%##U**XVG)Y/^_ @.KJJUW)$9MWNE3#T@4ZD,\G1L4LNBDAW=*E.2^&[S_0
M-4%GE*0NV&=/S:;QYS%^0.$%EDG[Z;>9%9ZM/.C4DE2;\A1=OL^%5+*]-*\H
MS89>VXHP/^-$?@?BM"Q_M[T'6$;>J@]?X>8=5=_PPJ]M4:(N/3E@XP&S<1&)
MT6(5$6"Y'_4Z+):4-6Q'+7>/[WMB="!(Y>*[C]U^PS=,]+N?KR_O?NOE?+SA
M6]I 2E\C'NT)_3OD(HX\+!L2R]E,LD-G0BP:X@:0BO%%MU3'P3L)%,= 4G3#
M[8"-J#/$&!%VI/1)7 'CHZ$+;51W8)]&G@ TV85AD._XTMCZL59?N!EI*Y9O
M/F/%6,A^VAA8@%$T(^>E:NGY>Z5JIE9=%Y3;4$^%UVJ_)AUQSUJK9=%I]0U<
MN[HR6+IVLGULY5_J=J(UM\1?*UU3&LO!UL)^6_03\ L1+9+YJL-*0KHK.'L5
M>RIYWI49;)+J/TU:*ZJ773OZ\"Z*:9<..VR'$2JR0NZ8$!/H7S+WB-R.-'*U
M=R?V[L0NZNNLU+XU\_P;%=EY<=U+ZUY:=UA:/[8PMD><#4EG>D_HC;HG=(-W
M.V\IQ^=V>D?JPMQ7NNAY0^&]LXKZ5#I"@E]DAQ__#U!+ P04    " "B@:52
MQP:AA04N   +R0( $    ')C=7,M97@Y.3%?-BYH=&WM?>M3&TFR[_<3<?Z'
M.HP]:\=(0@]  CR.BV7P<-=CL\"<N;M?3I2Z2U(=]T/3#V'M7W\SLZI;K2<"
M UV(FIC (/6C*C,K?YE969GO_NOCU^[U/R].V6_7OW]F%W]\^'S>93O5W=T_
M6]W=W8_7']47>[5Z@UU'/(AE(L. >[N[IU]VV,XP249'N[LW-S>UFU8MC :[
MUY>[P\3W]G:],(Q%S4W<G??_^1_O\#/Z5W 7_TUDX@GX)7+2N"J^'QXV_N>@
M!A?!5[O9=^]VLZO_JUIE7SZQ;AB,192(B(WW:_5:L[9?9]4J7M +W0G\^Q_O
M1BQ.)I[X=2<1WY,J]^0@.(KD8)@<^SP:R*#:"Y,D](_JH_R3)!S1GW2'#%P1
M)$?UU\?],$BJ-P+O/>J%GJL^Z'-?>I.C+CRY%TGU62S_+8X:#7B$^A,'<!2$
MD<\]]= $"=>'#^#30*BKQCR2'-[$](4[[]]Q%G ?AOX_OWG?]NOMQGZ]WFK!
MY[O\_>GWH>S)A!T>UAKO=D?O"Q.]U[ST-*ZE+V+V1=RPR]#GP?QT=M[_'/3B
MT?&/O+%:KQTV7F],/$UP390?HZ?T!RR.G%]W!ESL1]][<7TRB>KX7Z/VOZ/!
M#B-!^W5GAW$OP7_T_&ZDFPR/&LW.Z/OQ4(UG;Q]^1U8\+NF+XK9$(@XZ[5:G
MH21BYKM6:V]O;W]_7WVUE&F%]># <$1D_H(X0>7 /L@P=J0('"#7I1B%41*S
M,QG%"?M'RDD9-.O-!GP4\,"1W(.+XM2#BWC@LHLH'$L7[OPZ$A%7JHO]!E/P
M<!KQ7?FI__1$/SEJU&N=]NL'6UVN'#-BSZ\[^/@=^"CA/4^P7ABY(OIUI[[#
M'.%Y\8@[,ACD?X^XZV9_9_-0MU2=T//X*!9'V2_'3(MV'49*;XCPA\O&^LTP
MS[E5T*H=-%\?WPQE(JKX:N3C3<1'.RMD"\>^@FH%LFZTU&'4873T$T^3<'.I
M\40"(E'55)J^;+V8%ED!^.,^$ZHL6VQZHG^;$[Z__1 )0:_@I=G,-M?4KG!"
MM>[4"S]PY]L@"M/ K18G4M:D=O':)7/;\/4@-C]UFLV#X^Q!*\5GRU;+#,56
M\'0I_Y?37-]&T%Q?RQ>:L4Q@7,[Q_%U@'28R2(7+DI!Q=PQP(%B81@PQHQ]Z
M,F1A'U AD=7K\T_GU_0K&(Y2Q$?L:\" 8,XW!A1CR5"PD\MNM<TD(J7TX5+N
M36(9T]=NZ(_Q ^GS'ES!FO]H-BKL?H-&D,+7]0G11D J !)VPV-X2PQ3N9')
MD)U\:-4[]WP!C,\)_1Z@(W)!/>_?TN^)2*@)S,LN_(CP!X(/_ NX5(JUN85X
MN)IHYJWPI\/#!Z2*Q<,MPL/GM%J,Q,.+2,3HZ;EL%(6^C&%&[.+LBORBKU?,
MY0DG.!-)E/H<%#90XGYO0A!$$ /N=^K[QZW/S!<)CQ.8J,/H8N' G<Q!2(Y8
M#%3&P?"$G9QT+\L#((LX!JTABS@6<2SB;(PX,Z'!O>9>\["CPW]&@M%Y(!/)
M$8P0*( PX$3!=%QRSM Q =<,?35TNSKPV-2=, '\2SE!Q<F'@TZ]0E>0IP0*
MONIX/(Y9#%3TF!]ZPDE!5W<_MEL 1Q0M#Z,*(M,(4"<2"HL4 ($SZ(4W^%S0
M&-)%!VD$C-##$$$$W_OHA\%?.%QTQ:KB^PBW/^":PI#Q6S58BV+/05];%+,H
M9E',F-5B)%05_2;A>#*0#O@NY"Z!T@?<#<?" R<FDL!$P(#?SL^JS4V&\_-/
MAWO[Q_>.XVE,BS._"<'-\5+4VOGH3C[L8RP27;Q(^!S0+\P"FTD(URL09M-9
M"9A+."*P4Y%/&:.[.(BX3Z'-WYH-&R"T0&>!S@*=!;HM [I34,+*'_M+9U+0
M[M"K3F>?P70\[>,X/!X2HLA@+.($L2(V%!-^[(UE)GL==-K-YK+4GKGO?COY
MYY\GEQ\K# ?5KV'(M=EH'+,W'_ZX.O]R>G7%_CR_/'V;?_X[G[#]BDJ1J=ZF
MDW;>LX6<FPH[#YP:>_/EGU>G1Y?=/Z[>HGD!9@5*TV!2[8=P XA13X:C(8?'
M.")-R+9 KYH'$W831M_01@$#A/QP0&A1]."U4PYRB-XXOC$)71AV1,D^\.A^
MGMH3Z=2>;)-6[9IFTBM(GG_GD3-DK8:>- KN2&4!N2PL9 $-\RR@6D&:G\1'
M7_&*SJVOF%W!F\KH0^;4S8>=]@X[=9UUAIJ]?OPUC4 X!B%R/#<S$WB.%VM[
M5;!8?B^&@#" @K8T:9\8+-((;QF"F<LCP<3WD7 2M:NO&<E\P0-X03]%D>!N
MF(),@%6NA"* Z;!&D_DPA6%<N<4DAT$W,CAB,9<NNQ91- &^@1-081?#VL<:
MK+;3K[6??VH<U(_U--<^]4_]O&SPTV$!KT#V@<!H7&,TJY".H,WNRIKT@PKS
M>"*TF:[%OK9V*&PZ%N  K,!0)4D@-0<BP.4 _$A[<8(CP56K>;;^J0+9@/D5
M\)@X'>%"71:<R]<T2T"N!87R:';7%U7<<0IC":3@WV$V0SZF@)S [$1O@KZ7
M]L+41E44^AF7D#8M!L8DK/-X&-[ -9R!$/1@Z(-;D/:,_L,I +(1Q46,0;UJ
M/Q)(B&@LP0PAK1&2('K3#^<WRY9Z<LL2/)9=MV9HSE#XH2+=!.4$>5[UD%*+
M>VFD9".U.I(AR&Q!;<)PG32*!+T4QL$CMQKVJPZNJH*VU1I2[Q 652Q%77$$
MBJTTA(5H:BV;WI\"5C#02W-.>YO>E'_$N(-*,:X[0\Z1!] SDYN"0YNG1G%K
M$7Y! :["&R5),$X$OQ1Z<!5TEE'BTA%0BB+)5]VO["0(4AC9[X)$LK8I8V:U
MA=('=P&-1M,$RZ,XV7F;$V8M(N0SIM].5=.%4DT/B)-&SOAC,;'KS9ES"2/P
M4)07D\8F;Q^3&#-F^P;DN3>"-P_V#EM[];UBXOCZGVQC:JY[TR6I^4(F]M$,
M.6UL9X6WJF'%1G>6TV7;XCLE3&O[(CQ/M6;*BO&L1X_YQYS-)!JK)&.PJM T
M:]0KRO^GX$'[.-;^]< +>^1\#R396\I_)I]NDX'/&'PSN=._S%I[X[BV^,&\
M^5<P12\^5C\W=,[9?OTU.$<A."[@.^CD;S#AHZ*Y",2NJG0!Q KFI>BB*C/Z
MS9>K[N?NVQJ[1L]*[>C#+R[8E8- 6=>Q$-\8'Z$+JGT!$,^Y7&IP.?.Q<G!H
M\364RKUZTI0ZA^]427&U(M9^ NN#NV0%J[@,.$D8/1$!XTXBQP+F2G#6(WE2
M,197],FI8KTHA)N7;O5D.SSSV>R5PKLROY$\V)ARZH, !!J3ZG&.2^5A28)\
MP6.="$[NPNJ@(9X0C3)!&O&!J/; V?A6Y7UXR!'W;O@D/I[#[6=D>]UQ[3[L
MVS>S[I8LZ'5&WA^97_5[%MFPIIQ9L&1-.6O*65-N&TVY[* SQ=8PR+7TM!I%
MDC>STW@A*H]AZ$B(*H]\=C'DL6!-!?&;6G/WVY,<3W=CU@:@G_!5ZR;YRVP$
M\\?L4[)!9_<\],&*&,0,#+-LHROLT]Y6C9TP>"X^94 ;:Q'[>GF9;X[-#71F
M&L4C@11D!4,3#V:,N)+FJ4S-QF-!&&["U'/!",6MA%@"'E/X?11B99 Q'KA,
MX.$B'\6"3/8FVL#$]Q8L7(>>*P-<TO3 1*@=B7"$1AO8KX[$2'TQWIQMKX1Y
MT)G2=?. ,UF=^9MYPM:'ZH$9KMZZ#/HP,;1U9SDPY%X_)_\3;((;&295QU$I
M/@IB#Y-U;P^06C/0FH'6#+1FX+-:,\_##%P1T<NR"!K-9<=I4(/?5AI@(^OH
M%@M%/^/#)-L.]C8<" \4J%Q\;.20LCZ70\?1EL7N1+\O,9\)$PM$C, CXZ$:
M-^^+9*+V^T<)S-HC"N($U-B66[7PS#X(DR=IKUG;<[[:]<9(F=JSAS<-A+*:
M;\O2$&SDP91QK(HZ0KT_RWD $ND(85QA<>H,,:[HB"C!'.^A\'F"Z5ADO/BT
M[#!C"G?W;X9";?<#00J'G BKJSVP^N0T"DH K VQ'@8: X%TP]&7E.@W5Q#K
MF>;Z;6Y88;[%F]DS;,]UH_EA-Y/MAK'94&G-2VM>6O-R&\W+KCH<#8;4Q@>C
M[_GFU<F2]QBVW.# .1TVWS0TJH*@C=U&;\7Q],78X$#X#@P/#%NQ&_!>%00$
M+<;OPF-O/NU^N7@[%S LQ (7TRP?B"X;):U>+R>9SM^.@1J81PS20!%!LI45
M 7!6:,0.A3?*8GG*]D1CG.JO%2)[RW:0<Y>!G4[%32<H=!CP #>O'2$PG7\L
MH@FX'-+YYDW4UO7:6<F^"@T6<Z"],/PVS7X%<UF0M^'($9K@KHR=-(YUVG*L
M0XM9S3:X9(C/*$Y#.2]#P3WT8=)D&$8@AR)>%T<L6D0;Q12MM;-"<]NCCRNI
MLFV6CCWZ^$Q6RTP:\,%AI][::Y=<J>9NB'FJ<7Y:\26,5 :8GWKYY_E9":7[
M)VP<>FF0"!%A*,H/ W5402$'F 1@"$PHJ<H92C$6.4KB=IHC(X<>C5NL43I@
M'N9N;;A=^9LZ2(-G]%8.<Y25Q49 T.CKAH1S?4]\EWIX&= 5AJOB=$(_A\!.
M98/ARVAKTP?+*TYH6S _9++95IF%->O$6R?>.O'/:LT\#PS[.A(!Y6EH_\,)
MAWADL^#"DG,R"42$O@PZH-/\BPPU$ Z*Z2ZU#7U)&6?OP^(R/$JR8F_Y8<^I
MLXYNWF'VW+551-_XW<ON6]PV2=:^GWQ0\M@QNSL[,[Y(@,R%+<ZP@I#L1+('
M(_/X]*AY97XF83#08Z:#SW30\6XG%6D^%WI"Q3'_*.OOE/;[E*DLSV;OP>8X
MF^UA/#>SQ?KCUF0IT1]_%@:++L*7^ZU%1W6FGL"&\?MIJ3P?[ CF\R2-9C-%
ML]V,V.'>-#%VL8C!ZGV/>*8B+)4>*#FEM-BOJEUK[M^I7=76IUN<%E.WWYR\
MB]/>HB;I -%PHX%J&NFEK^:^\[[)W^W"3>]W[W-O3]W+IG50T!P>)2$5A>&#
M$,,H-OG#)G^8[P,_-P/,QHVL$5;VFC'3#"M6/Z;==3!8PC3B@V)IJ <R\;+#
M::VY[(J%4V;S1ZP6<H7]LZ^?S[[^O\J])YU-Z990$IEM5%40ZR_/59%Z(*KD
M036,5<W,O#CMF1TESO9JNMP=F9L\N*6R60-4\.SU\[7.*JK2P7<)AC)6&:#J
M:F*3"F.J8FBQPMB2[D#=RVY>\& ]Q:\I[0*?MR".9)*K#;>Q5!7C8,4*(HG.
MAH]K[#S(?0=566^&IK]DLC,K5%GMAB3TJ$*>6UD(?C)7NJ #$B04GIVCGH,N
MPS07V0=[#\^B ?T<O6]&Y0SS8WU(./WBZD'.<8I]5K)X(@42UQ*GD*&CET]O
MMSD7/[S3.E([>7R E,,+-,>:BF,5UDNEY\944AP).<^+W#U2!?I4_-(DCV:-
MX6+'L&H,J_N2/M88GKX(B &UADMVQFPP?&LL2^N-66_,>F-;Y8WE8?#EX6BU
MW:Q//@:J&@.>PM2U;Y7'LECWML+^;QH(ME?MO(O3T:+$8/@2M7YUJ$;9:(*V
MG0MGDC0D0XQECK)I@ITM$T^X1VR38MDT^"-V4K!A*PSS%:J?>4^ )W)9,',S
MV_:*Y@IV]6EV6O(4CWAR1R6M7:E3G4"PN1COA\-FYVWU \<SLM?H*U!Z>7=J
M")/=>Z&]!^U=XKY\;;;V[[-,9&O4:YVV$;K>8N"=,; +OI:$-0WJ>CO0[^$F
M%%J\>AR\.E^*-E=TJKVYXDQ5X1#^?/>&GBA4]0<U*WCD31"=FK><+S=4GQJC
M-JPZM2Z%=2D,6S-FNA2WY=ED#D9!N<_FV^QM>%XVR&/8Z^/0"X=F9PH^+Y2$
M_F6A(/3II[/+^Q4 ]-/-6K@DDT@E:'P#)R$6T](<[,WUW\_?5F%LB""N;KO9
MC[@#7TY4/;_*% ++SP>RY5?6A3:ID:MNTIKS^&X%D9<HHA5'KE<_8W&)JF+=
M-LIJDGJW)I$UB:Q)M(TFD?)Z,X-H9:MLW*9?V?I[X;4+IW((9AZJIL=:M%J\
M.B[4N"#//'0<F,T:.X2=)&N37ZAP1J%EGTBX].+L=-1ODU'X7?+J>>"FCD24
M.B,3B65H^Z8 O6\QSTA0$\^\(^(T>WN^F,C29NSS&$YE\+!;()8/45E,TQJ)
MV,@PH92-C.5^Z DG]>"!6:$]W5:=PL'B.^(H==' (W+.I *OAQL2.98)_-&3
M>24^KC]4+?94=]00C$A!!^PB[$9*M4'B5"KP1KGJIQ&E813D[?F9@;>W,C77
M##S+V\U>SK6;594V_Z%K7-):.%W2<]8::N:<=GEN9IH]&_8 D_KYI^\853;(
MPGHY1[L6RL?Q>%A1/>3%7RGFEM+.ZEP_^8WB,#=8R?95I[-7.\SZT]]K2)OU
M[25S8E:Q5V;:[;YJM_9KC6PD3-WP43@"PU79/75UZ%Q2-;=84&KI*)(@2IBR
MZNI&S%$8YW7-Z#&OFG#G7OYL/!DDQ_#:=*23+QU/E6O1)\[@D6/<!1]Y7-<A
M1M,U]'VX/$Y"YQLCA%/9 KYJE(XLN!1T!MUE5W3110K3Q6&>#"*AGD,VCV[3
M !;3F>A%@'\330\\ Z^*.H?]?BP2[.Y O$X3Z5'T,#.5\];K<8U-.S<XJZ4#
M2/1-**@$BS359=3"H#JDLC2TG12G66%G_*"?!H46[]3O 88=H^4*ZV PQ#&W
M;"F:9Z#(+&I;U+:H72)J7X+S&:0B/EI6FW+=V[K3=I3Z!+4G'1'0J1'U2*9@
M_+"VG\-;YE]1QREU,"5F8HEG-0? C5IGX1DQ]P$&121#PBL%P>?!IL^_H6.X
MX2 @\'K5KK7S-]")B>+L\AGA!I".I"BDS!NH9GM@$1U;5?7>' %@K\K?Z#@'
MDFFF/:<<"2H(B\E\#C#=Q1(Q"HIQ'AJ.9VF=0W:EV'ITAD93&^":RV$XO65C
M"M47*+39\RWHFJ^'+.A:T+6@6R;H_LS]T?%'=@J^$2#F]%S-VFC^Y2H4$?HQ
M&G /#@H.Y7T1%_RGQF:0>[O7^ZJQ7ZOG#P-_-4Y[F;% #F!VP"B;21:QI\"K
M?A]VP2D,, " ]8&125RXN*XO1I13 Z)OA3_RPHD0] !XOH)1)XR3>/[XZZN]
M NU@I&HW@1H@PM7X"?86)S>6O.UJCS+,BP^&1WIQJ.JFRUZJS06J)JO/WDYG
MJ:F&1"#>N>#=BP!]:_T=FA1#, $<G"I=1S11GCZ_X9$+7O;O/$C[W$G22-6#
M+?0"ITGF+W)S@T%S)BGPSF5!2@&-XEZ8WIA1CCKF]Z!K7N1#+A990RC-#1 "
M$!K5!_PK^NYJEKJ7$CYEG@IZ<'G1=E<'3&Z4B&7$RXDF@]5V5;XB=/6^^<@%
M1T8?%J(NTN^E4:P"(?"]MKN0$KKS$H@)B"P9*8JF\)U^(Q*]F+I4W,6"U]17
MO*9@2RY; '3<VK7VU#. &&M/67O*VE,EVE.?R)XZN:,]]4D$""D$'EDU<QSP
M6,Q;5&"_+,8?[FI1M0M(L+E!A>:+Q@2TK31NRUO-FR6&S>$/&S;W,T].IA7]
M9L;=I^UW91=X8L"].;)[L!2H)$G^UMR:(6Q$0L3I"(^D4)0%;85DN$F%V_O4
M'; 8NQ48^_)T],)^)^Z=Z6@E+F]/3F..(W+,E-X*)F"B_I7*B,S5N**]E.GR
M*U3J7&+6:TV%"Y/J9[J+NB)4?@$QZ,4:NLNKKG2,E*NG,W0?D"K6T#7'T'U.
MPFZBH?M%).QS&&]HX.+5'B:<H.7XJMW$6G _9L1R%F3/I-R5]NW[<O/!H'GK
M-G\@7Q%86O6HN5@C3U2XC>!@ 7@*R2+3X$RAFS<9I'C+-/*5;<VILUXJ5C,-
MU(SX1,/BLOC2-*:5;QT6(F[K=_5^* ?8P'3<D\A)8];-Z*H*>GP=BV@LQ<W#
MI<YNC.JM6GU_%MAG4*O1J+5;KX^+EN+,]\W#6N=PS?>M>JUSL.9[\"7WUG_=
MZ!2^WU6#7&:"9#=J*A'#X]"3+JO7VONCA&6J(+M R\C::ZC&V]HK:(=[^26K
M( "+.HOH=DNZ6&<._YZ57?S@R:7WFFJ4?@%%M,;LL9QX$CWBQY8'Y?+@2I5R
MM6PHF0T)3U*[&$KFPI?N-?L2U@ILL&"]R)$-&+"1D[PA2&!!8KLPRF:#*L8W
M+;IM.5(V1[J77<N$LIF0E5DC']BRHVQV (#76^UF_:#=L2!N$%]T]2F[/ P!
M\7])'WYV>=0+=R^$3[6ZYCZSW"J;6]=_/V>7NY=4)0WKG5%-,LN6LMGR5>^T
M7RZT<-EM6NZ4S1VR #I[!ZU&W5H !O&%2L7;Y5$V&^8L@*NO7<)^^-?RIFS>
M-#_OMCXS[%A@>5$V+U:"O(7XTGF#$+_7ZC0ZK::%>(/X@A#?MLNC;#8@LD_]
M^8_A_%^_Z,8ZEE-E<ZKQ6?GT[,W%Q^KG1M:SD^W77[^UW"F;.]8$,)<W9 (T
M#YJ=_0-K AC$%S0!.G9YE,Z&#P>=>N[D?Q+^[I<+L@*R+]1'EE%E,PHL@(N/
M)];?+YT1:X+ZC9YE3]GL(;QOU/<.VM;E-XDOB/>'=GF4S8:YJ+Y.T;.1?5/X
M0Y%]^/\79I/V#&"'[A(#&&]]>_.X0UA_<%#O-"S6F\07Q/J9I K+AU+XP+K8
M13,/ZOMA$,Y&^"V+RF:1#>R;S)T"_(N!KA"&-6\L9\KF#$%_NW70:+<L]!O$
M%X)^:QJ7SX</K7I'N?F6&:4S0]6:P?(Z.!GL.RCL">[2V3)%=QO -X<KMY3>
M.J/_<@N@W3SL'"Y6)[.&0-ELO#CIGI^=VSU^ UCQ,8W&'#S+1KM];+U^$SC2
M356MZ>HY3 *TW57"!X*U[+D],]AS2FTKJ7EXWB2^^5NS8:, AC'JR\D"YC]&
MN_2G*]-QQ,C, >G#_BWH-$05I16.J$9[[&,;%"Q_R+P4:SCK2_ HT!%V6$7A
M%-5(8&5WCDWFHI!ZO^978A+1$=O4R!IQ*F:92 ?@XZ!^[*8T,@Y4"AT>.3((
M?5YAA#!'S,5_O-3GO9GFZ+9E_7KOL!>F"5.5,C_(,,9.MX[R#W]T&D_LYLY/
M0<F,Q 9"+ Q0M@:3:C^$JT"W]F0X&G*XU1%IHOL5J<KCGL!V/P-,LI))S%PA
M1LS!YLE55\*C1YX,L#<Q%AN/$AE3:57\!KL$L2%,!_L&R'Y?1$ +Y> E0WCB
M"$N4Z[;"NGT/XZP7A=QEV$B@#WHS5-T0X$L<3@_>I+L,NRXL*NIY$(/:E'T8
M,:R@-/!%P@)LZ%S3+*0"Z4$"8P"GDO6QHX0?>L))/=7Y("\R6^A9=*0HM;X>
M<):\ 1S&5[\Y^7#8[+S5*ZU"Q67[,HH36(;P])-W<=J;>18QOK/_^IB-D6XP
M! T!2J9VWC?YNUVXZ?WN?>[MZ2G0$T@_Q%A %WM:CY(P KJ#C1-BFPTD/X&.
M;G&-Y*A@LZ:>0/(*5"%<H2_S4R\!AHMLSYW8U\"QJ6Y4G.1BRFVXQX71$<^*
MK9@R-5@IZ-?*,HVJ*MU/U9[6FW%M,PY1UNP2EM!;JID<L.['=@M&-Y0]B;19
M11 @P#0RP5 AW*=YQ>8JI&QOOX3W%QN'81%K8E>5:C\G* %9EW58YAPE""1B
M03A4S]A<6:AN"L6F8"13 ^$[$HP3>/1NP'O5$0=.)_R[\#+9VJ0H.'ASH3_F
M8'W* LS><@OJBL;^WMN5ES\MS7&-H3Z0U>OS3^?7M"_M>-1+ C_MA>Z$*!8
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M$>'"R@%3+7,@OXAEI#0L@!$3L%!H^J0?%EE/OK3*A:,HML8<ER?\6%$:5/-
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MGGL\,\"[,."N+U6T1^*O>.,#3;PXN24BL-D0?XCA5\(3#KK=W3"@J@,<__C
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M<RTR,#(Q,#4P-5]L86(N>&UL4$L! A0#%     @ HH&E4OC(GEH%!0  WBL
M !4              ( !)0P  ')C=7,M,C R,3 U,#5?<')E+GAM;%!+ 0(4
M Q0    ( **!I5(#Z@I-UQ   +F$   4              "  5T1  !R8W5S
M+3AK7S(P,C$P-3 U+FAT;5!+ 0(4 Q0    ( **!I5+'!J&%!2X   O) @ 0
M              "  68B  !R8W5S+65X.3DQ7S8N:'1M4$L%!@     %  4
*10$  )E0      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
